Researchers Explore Vitamin B3 as a Potential Treatment for Glioblastoma

Edward Waldner's journey began with a subtle yet alarming shift in his health. Despite leading a busy life, he found himself battling persistent exhaustion at age 55. Initially suspecting sleep apnea, he soon noticed troubling changes in his mobility, prompting a visit to the Emergency Department.

It wasn't long before a doctor delivered the sobering news: Waldner had a brain tumor, and further tests confirmed it was glioblastoma, an aggressive cancer notorious for its poor prognosis. Standard treatment typically involves surgery, radiation, and chemotherapy; however, the nature of glioblastoma often makes it difficult to eradicate, with a high chance of recurrence after treatment.

In a bid to combat this formidable illness, researchers at the University of Calgary are examining the effects of vitamin B3, or niacin, as a potential supplementary treatment. Waldner became part of a clinical trial that aims to evaluate how high doses of this vitamin might help restore immune function compromised by the tumor.

The research team, comprising Dr. Gloria Roldan Urgoiti, an oncologist specializing in brain cancers, and Dr. Wee Yong, a neuroscientist focused on the immune system's interaction with the brain, embarked on this study to tackle a key challenge with glioblastoma: its ability to weaken the immune response that is meant to combat cancer cells.

Initial findings stemmed from experiments conducted in Yong's lab with mice, which showed promising results as niacin appeared to extend survival rates. This preliminary data paved the way for the Phase I and II clinical trial now underway, focusing on both safety and effectiveness.

Dr. Yong explained, "Normally, the immune system works to prevent tumor growth; however, glioblastoma suppresses this response." The hypothesis is that niacin could rejuvenate immune cells, allowing them to regain their ability to target and kill cancer cells effectively.

The current trial examines a controlled release formulation of niacin alongside standard chemotherapy and radiation. The primary objectives are to determine the safe dosage of niacin and assess whether it improves progression-free survival rates for patients—meaning, how long patients can live without their cancer worsening.

Researchers set a benchmark for the trial's continuation, planning to halt the study if progression-free survival did not improve by at least 20 percent compared to past data. Remarkably, early results showed that 82 percent of participants maintained stability in their cancer at the six-month mark, exceeding the threshold with a 28 percent increase in survival without progression compared to earlier studies.

As Waldner continues to participate in the study, he expresses gratitude for being part of the research initiative. "I’m doing this not just for myself but to help others," he shared, reflecting on the mental strength gained from being involved in such research. After his surgery, he faced a grim prognosis, and the trial has provided him with a sliver of hope amid uncertainty.

Despite the encouraging early findings, Roldan Urgoiti emphasized caution, noting glioblastoma remains one of the most aggressive cancers, with 20 years of stagnant survival rates for affected patients. "Any potential treatment deserves exploration, but it requires adherence to strict protocols and safety monitoring." The detailed findings are documented in the Journal of Neuro-Oncology.

Although niacin is a commonly available vitamin, researchers warn against self-prescribing high doses, as large quantities may lead to toxicity and unintended health consequences. The ongoing trial is meticulously controlled to ensure patient safety.

Researchers aim to enroll a total of 48 participants by the trial’s conclusion, expected by late 2026 or early 2027. For Waldner and others in similar positions, this study represents not just a potential treatment avenue, but a chance to contribute to the broader fight against a tenacious illness.

The endeavor is supported by the Canadian Institutes of Health Research and the Alberta Cancer Foundation, affirming the commitment to advancing treatment options for glioblastoma.

Materials provided by University of Calgary. Note: Content may be edited for style and length.